Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Mezigdomide + bortez increases cell death thru disruption of multiple cell cycle phases; MEZI/BTZ/DEX triplet superior to single agents in antiproliferative/proapoptotic activities, substrate degradation depth & kinetics.”
Title: Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma
Authors: Chad Bjorklund, Marta Larrayoz, Jian Kang, Hsiling Chiu, Natasha Shtraizent, Lei Wu, Shirong Li, Chih-Chao Hsu, Junfei Zhao, Michael Amatangelo, Tracy Chow, Krista Wollerman, Ram Kumar Singh, Sneha Sridhara, Shailesh Dudhgaonkar, Prakash Subramanyam, Kaushik Ghosh, Paul Richardson, Nizar Bahlis, Anjan Thakurta, Patrick Hagner
You can read the Full Article in Blood Neoplasia.
You can find more posts featuring Robert Orlowski on OncoDaily.
